Cargando…
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlot...
Autores principales: | Boutsikou, Eftimia, Kontakiotis, Theodoros, Zarogoulidis, Paul, Darwiche, Kaid, Eleptheriadou, Ellada, Porpodis, Konstantinos, Galaktidou, Grammati, Sakkas, Leonidas, Hohenforst-Schmidt, Wolfgang, Tsakiridis, Kosmas, Karaiskos, Theodoros, Zarogoulidis, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589083/ https://www.ncbi.nlm.nih.gov/pubmed/23467839 http://dx.doi.org/10.2147/OTT.S42245 |
Ejemplares similares
-
New dilemmas in small-cell lung cancer TNM clinical staging
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013) -
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013) -
The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013) -
Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis
por: Zarogoulidis, Paul, et al.
Publicado: (2013) -
Successful application of extracorporeal membrane oxygenation due to pulmonary hemorrhage secondary to granulomatosis with polyangiitis
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013)